SCHEMBL9540629

SCHEMBL9540629

CC(CCO)NC(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CACNA1F O60840 1/20 0.38
CHRM2 P08172 1/20 0.38
CHRM1 P11229 1/20 0.38
ADRA2B P18089 1/20 0.38
CHRM3 P20309 1/20 0.38
ADRA1A P35348 1/20 0.38
HRH1 P35367 1/20 0.38
OPRK1 P41145 1/20 0.38
CACNA1D Q01668 1/20 0.38
SLC6A3 Q01959 1/20 0.38
KCNH2 Q12809 1/20 0.38
CACNA1S Q13698 1/20 0.38
CACNA1C Q13936 1/20 0.38
SCN5A Q14524 1/20 0.38
DPP4 P27487 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18997681 0.85 CACNA1F (0.35) CACNA1FCHRM2CHRM1ADRA2BCHRM3
SCHEMBL438988 0.78
SCHEMBL7775143 0.78
SCHEMBL6200856 0.78
SCHEMBL7775114 0.76 CACNA1F (0.39) CACNA1FCHRM2CHRM1ADRA2BCHRM3
SCHEMBL12403740 0.76 DPP4 (0.32) DPP4
SCHEMBL14176514 0.76 CACNA1F (0.39) CACNA1FCHRM2CHRM1ADRA2BCHRM3
SCHEMBL24191897 0.75 CACNA1F (0.35) CACNA1FCHRM2CHRM1ADRA2BCHRM3
SCHEMBL24191896 0.75 CACNA1F (0.35) CACNA1FCHRM2CHRM1ADRA2BCHRM3
SCHEMBL24191892 0.75 CACNA1F (0.35) CACNA1FCHRM2CHRM1ADRA2BCHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4405581-A Process for the selective removal of hydrogen sulfide from gaseous mixtures with severely sterically hindered secondary amino compounds EXXON RESEARCH AND ENGINEERING CO. (US) 1983-09-20 US claimed
US-12427472-B2 Process for removal of acid gases from a fluid stream BASF SE (DE) 2025-09-30 US disclosed
CN-114173908-B Method for removing acid gases from fluid streams 巴斯夫欧洲公司 2025-04-01 CN disclosed
WO-2025038904-A2 REDUCING CONSUMPTION OF SULFIDING AGENT IN HYDROPROCESSING OF BIOFEEDSTOCKS ExxonMobil Technology and Engineering Company (US) 2025-02-20 WO disclosed
US-12138583-B2 Process for removal of acid gases from a fluid stream with a liquid absorbent comprising a piperazine ring BASF SE (DE) 2024-11-12 US disclosed
CN-113453784-B Method for removing acid gases from fluid streams 巴斯夫欧洲公司 2024-09-13 CN disclosed
US-20240042375-A1 PROCESS FOR REMOVAL OF ACID GASES FROM A FLUID STREAM BASF SE (DE) 2024-02-08 US disclosed
EP-4028148-B1 PROCESS FOR REMOVAL OF ACID GASES FROM A FLUID STREAM BASF SE (DE) 2023-11-15 EP disclosed
US-20230286997-A1 Compounds for the Treatment of Cancer and Inflammatory Disease SHY Therapeutics LLC 2023-09-14 US disclosed
EP-3927450-B1 PROCESS FOR REMOVAL OF ACID GASES FROM A FLUID STREAM WITH A LIQUID ABSORBENT COMPRISING A PIPERAZINE RING BASF SE (DE) 2023-06-07 EP disclosed
US-20170174699-A1 COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE SHY Therapeutics LLC 2017-06-22 US disclosed
EP-2825286-A1 AMINE TREATING PROCESS FOR ACID GAS SEPARATION USING BLENDS OF AMINES AND ALKYLOXYAMINES ExxonMobil Research and Engineering Company (US) 2015-01-21 EP disclosed
CN-104284706-A Amine treatment process for separating acid gases using mixtures of amines and alkoxyamines EXXON MOBIL RES & ENG CO 2015-01-14 CN disclosed
US-20130243676-A1 AMINE TREATING PROCESS FOR ACID GAS SEPARATION USING BLENDS OF AMINES AND ALKYLOXYAMINES EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) 2013-09-19 US disclosed
WO-2013138443-A1 AMINE TREATING PROCESS FOR ACID GAS SEPARATION USING BLENDS OF AMINES AND ALKYLOXYAMINES EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) 2013-09-19 WO disclosed
US-20110202328-A1 System for the determination of selective absorbent molecules through predictive correlations EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) 2011-08-18 US disclosed
US-20110202328-A1 System for the determination of selective absorbent molecules through predictive correlations EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) 2011-08-18 US disclosed
WO-1993010883-A1 LEAN ACID GAS ENRICHMENT WITH SELECTIVE HINDERED AMINES EXXON RESEARCH AND ENGINEERING COMPANY (US) 1993-06-10 WO disclosed
US-4405581-A Process for the selective removal of hydrogen sulfide from gaseous mixtures with severely sterically hindered secondary amino compounds EXXON RESEARCH AND ENGINEERING CO. (US) 1983-09-20 US disclosed
EP-0087208-A1 A process for removal of hydrogen sulfide from gaseous mixtures with severely sterically hindered secondary amino compounds EXXON RESEARCH AND ENGINEERING COMPANY (US) 1983-08-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12427472-B2 Process for removal of acid gases from a fluid stream C5, C1S, C9 CACNA1F 2995/4885CHRM2 224/4885CHRM1 133/4885
US-20230286997-A1 Compounds for the Treatment of Cancer and Inflammatory Disease MAPK6, MAP3K6, MAPK4 CACNA1F 4878/4885CHRM2 4708/4885CHRM1 4749/4885
US-20240042375-A1 PROCESS FOR REMOVAL OF ACID GASES FROM A FLUID STREAM C5, C1S, C9 CACNA1F 2995/4885CHRM2 224/4885CHRM1 133/4885
US-12138583-B2 Process for removal of acid gases from a fluid stream with a liquid absorbent comprising a piperazine ring AVPR2, HRH2, SLC43A1 CACNA1F 2044/4885CHRM2 38/4885CHRM1 55/4885
US-20170174699-A1 COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE MAPK6, MAP3K6, MAPK4 CACNA1F 4878/4885CHRM2 4708/4885CHRM1 4749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.